Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer | Zendy

Gϋnter von Minckwitz | Zendy; ChiunSheng Huang | Zendy; Max S. Mano | Zendy; Sibylle Loibl | Zendy; Eleftherios P. Mamounas | Zendy; Michael Untch | Zendy; Norman Wolmark | Zendy; Priya Rastogi | Zendy; Andreas Schneeweiß | Zendy; Andrés Redondo | Zendy; Hans Holger Fischer | Zendy; William Jacot | Zendy; Alison Conlin | Zendy; Claudia Arce-Salinas | Zendy; Irene Wapnir | Zendy; Christian Jackisch | Zendy; Michael P. DiGiovanna | Zendy; Peter A. Fasching | Zendy; John Crown | Zendy; P Wülfing | Zendy; Zhimin Shao | Zendy; Elena Rota Caremoli | Zendy; Haiyan Wu | Zendy; Lisa H. Lam | Zendy; David Tesarowski | Zendy; Melanie C. Smitt | Zendy; Hannah Douthwaite | Zendy; Stina Mui Singel | Zendy; Charles E. Geyer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Author(s) -

Gϋnter von Minckwitz,

ChiunSheng Huang,

Max S. Mano,

Sibylle Loibl,

Eleftherios P. Mamounas,

Michael Untch,

Norman Wolmark,

Priya Rastogi,

Andreas Schneeweiß,

Andrés Redondo,

Hans Holger Fischer,

William Jacot,

Alison Conlin,

Claudia Arce-Salinas,

Irene Wapnir,

Christian Jackisch,

Michael P. DiGiovanna,

Peter A. Fasching,

John Crown,

P Wülfing,

Zhimin Shao,

Elena Rota Caremoli,

Haiyan Wu,

Lisa H. Lam,

David Tesarowski,

Melanie C. Smitt,

Hannah Douthwaite,

Stina Mui Singel,

Charles E. Geyer

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1814017

Subject(s) - trastuzumab emtansine , trastuzumab , medicine , antibody drug conjugate , oncology , breast cancer , chemotherapy , metastatic breast cancer , cancer , antibody , monoclonal antibody , immunology

Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)-targeted therapy have a worse prognosis than those who have no residual cancer. Trastuzumab emtansine (T-DM1), an antibody-drug conjugate of trastuzumab and the cytotoxic agent emtansine (DM1), a maytansine derivative and microtubule inhibitor, provides benefit in patients with metastatic breast cancer that was previously treated with chemotherapy plus HER2-targeted therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research